- Markets
- Healthcare
- VISTAPH
VISTAPH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vista Pharmaceuticals To Issue 48.9 Million Warrants At 12 Rupees Each
Feb 19 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
VISTA PHARMACEUTICALS LTD - TO ISSUE 48.9 MILLION WARRANTS AT 12 RUPEES EACH
Source text: ID:nBSEc1TY3f
Further company coverage: VIPH.BO
(([email protected];;))
Feb 19 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
VISTA PHARMACEUTICALS LTD - TO ISSUE 48.9 MILLION WARRANTS AT 12 RUPEES EACH
Source text: ID:nBSEc1TY3f
Further company coverage: VIPH.BO
(([email protected];;))
Vista Pharma Gets License To Make Sulfamethoxazole And Trimethoprim Tablets For Export
Nov 14 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
GETS LICENSE TO MAKE SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS FOR EXPORT
Source text: ID:nBSE7FpqRB
Further company coverage: VIPH.BO
(([email protected];))
Nov 14 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
GETS LICENSE TO MAKE SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS FOR EXPORT
Source text: ID:nBSE7FpqRB
Further company coverage: VIPH.BO
(([email protected];))
Vista Pharmaceuticals To Issue Upto 17.4 Million Shares At Rupees 12.96 Each On Preferential Basis
Sept 6 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
TO ISSUE UPTO 17.4 MILLION SHARES AT RUPEES 12.96 EACH ON PREFERENTIAL BASIS
Source text for Eikon: ID:nBSE6zV63X
Further company coverage: VIPH.BO
(([email protected];))
Sept 6 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
TO ISSUE UPTO 17.4 MILLION SHARES AT RUPEES 12.96 EACH ON PREFERENTIAL BASIS
Source text for Eikon: ID:nBSE6zV63X
Further company coverage: VIPH.BO
(([email protected];))
Vista Pharmaceuticals To Consider Proposal For Raising Funds By Way Of Issue Of Preferential Issue Of Shares
Sept 1 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
TO CONSIDER PROPOSAL FOR RAISING FUNDS BY WAY OF ISSUE OF PREFERENTIAL ISSUE OF SHARES
Source text for Eikon: ID:nBSErkcb7
Further company coverage: VIPH.BO
(([email protected];))
Sept 1 (Reuters) - Vista Pharmaceuticals Ltd VIPH.BO:
TO CONSIDER PROPOSAL FOR RAISING FUNDS BY WAY OF ISSUE OF PREFERENTIAL ISSUE OF SHARES
Source text for Eikon: ID:nBSErkcb7
Further company coverage: VIPH.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vista Pharma do?
Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations, including a range of generic drug products. Founded in 1992 with a vision to expand globally.
Who are the competitors of Vista Pharma?
Vista Pharma major competitors are JFL Life Sciences, Vivo Bio Tech, Ind-Swift, Godavari Drugs, Shanmuga Hospital, Biofil Chem & Pharma, Rajnish Wellness. Market Cap of Vista Pharma is ₹66 Crs. While the median market cap of its peers are ₹71 Crs.
Is Vista Pharma financially stable compared to its competitors?
Vista Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Vista Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vista Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vista Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Accounts Receivable
How strong is Vista Pharma balance sheet?
Balance sheet of Vista Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Vista Pharma improving?
Yes, profit is increasing. The profit of Vista Pharma is -₹3.06 Crs for TTM, -₹4.51 Crs for Mar 2024 and -₹5.66 Crs for Mar 2023.
Is the debt of Vista Pharma increasing or decreasing?
The debt of Vista Pharma is decreasing. Latest debt of Vista Pharma is ₹4.21 Crs as of Sep-24. This is less than Mar-24 when it was ₹7.8 Crs.
Is Vista Pharma stock expensive?
There is insufficient historical data to gauge this. Latest PE of Vista Pharma is 0
Has the share price of Vista Pharma grown faster than its competition?
Vista Pharma has given lower returns compared to its competitors. Vista Pharma has grown at ~8.95% over the last 2yrs while peers have grown at a median rate of 14.0%
Is the promoter bullish about Vista Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vista Pharma is 21.19% and last quarter promoter holding is 21.19%.
Are mutual funds buying/selling Vista Pharma?
The mutual fund holding of Vista Pharma is stable. The current mutual fund holding in Vista Pharma is 0.02% while previous quarter holding is 0.02%.